Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 798 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 798 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $29,629.74. Following the transaction, the insider now directly owns 345,188 shares in the company, valued at approximately $12,816,830.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

William Banyai also recently made the following trade(s):

• On Tuesday, April 2nd, William Banyai sold 327 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $10,705.98.

Twist Bioscience Price Performance

Shares of TWST traded down $1.54 during mid-day trading on Tuesday, hitting $43.13. 1,808,210 shares of the company’s stock were exchanged, compared to its average volume of 997,886. Twist Bioscience Co. has a 52 week low of $11.81 and a 52 week high of $44.92. The company has a market cap of $2.51 billion, a PE ratio of -12.84 and a beta of 1.64. The company has a 50-day simple moving average of $34.11 and a 200 day simple moving average of $31.34.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The business had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. During the same quarter last year, the firm earned ($1.06) earnings per share. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent research reports. Barclays raised their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. Evercore ISI increased their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday. Scotiabank boosted their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday. Finally, The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $42.50.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Artisan Partners Limited Partnership grew its holdings in Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after purchasing an additional 1,961,621 shares during the period. Invesco Ltd. raised its stake in Twist Bioscience by 1,496.2% in the 3rd quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock valued at $16,836,000 after acquiring an additional 778,944 shares during the period. ARK Investment Management LLC lifted its holdings in Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after purchasing an additional 427,274 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc bought a new position in shares of Twist Bioscience in the fourth quarter valued at about $11,956,000. Finally, Norges Bank acquired a new stake in shares of Twist Bioscience during the 4th quarter worth about $10,766,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.